A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial

RCT (n=176) showed no difference between glargine U300 and U100 in mean daily blood glucose (BG, 186 ± 40 vs. 184 ± 46 mg/dL, P=0.62, primary endpoint), percentage of readings within target BG of 70–180 mg/dL (P=0.3), length of stay, or insulin total daily dose (p=0.74).


Diabetes Care